Kymera Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 14.37 million compared to USD 34.87 million a year ago. Basic loss per share from continuing operations was USD 0.25 compared to USD 0.6 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
38.71 USD | +2.14% | -0.08% | +50.31% |
03/05 | Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53 | MT |
02/05 | Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+50.31% | 232.55Cr | |
+22.13% | 4.5TCr | |
+0.58% | 4.26TCr | |
+46.00% | 4.18TCr | |
-4.27% | 2.9TCr | |
+10.24% | 2.61TCr | |
-20.74% | 1.9TCr | |
+5.35% | 1.28TCr | |
+27.94% | 1.21TCr | |
-3.83% | 1.18TCr |
- Stock Market
- Equities
- KYMR Stock
- News Kymera Therapeutics, Inc.
- Kymera Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023